Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial by unknown
Roth et al. Nutrition Journal 2013, 12:47
http://www.nutritionj.com/content/12/1/47RESEARCH Open AccessRandomized placebo-controlled trial of high-dose
prenatal third-trimester vitamin D3
supplementation in Bangladesh: the AViDD trial
Daniel E Roth1*, Abdullah Al Mahmud2, Rubhana Raqib2, Evana Akhtar2, Nandita Perumal1, Brendon Pezzack1
and Abdullah H Baqui2,3Abstract
Background: Antenatal vitamin D status may be associated with the risk of adverse pregnancy and neonatal
outcomes; however, the benefits of vitamin D supplementation during pregnancy remain unknown.
Methods: We conducted a double-blind placebo-controlled randomized trial to evaluate the effect of high-dose
prenatal 3rd trimester vitamin D3 supplementation on maternal and neonatal (cord blood) serum 25-hydroxyvitamin
D (25(OH)D) concentration (primary biochemical efficacy outcome) and maternal serum calcium concentration
(primary safety measure). Eligibility criteria were pregnant women aged 18 to <35 years, at 26 to 29 weeks
gestation, and residing in Dhaka, Bangladesh. 160 women were randomized by 1:1 allocation to one of two parallel
intervention groups; placebo (n = 80) or 35,000 IU/week of vitamin D3 (n = 80) until delivery. All participants, study
personnel and study investigators were blind to treatment allocation.
Results: Mean maternal 25(OH)D concentration was similar in the vitamin D and placebo groups at baseline
(45 vs. 44 nmol/L; p = 0.66), but was significantly higher in the vitamin D group vs. placebo group among mothers
at delivery (134 vs. 38 nmol/L; p < 0.001) and newborns (cord blood: 103 vs. 39; p < 0.001). In the vitamin D group,
95% of neonates and 100% of mothers attained 25(OH)D >50 nmol/L, versus 21% mothers and 19% of neonates in
the placebo group. No participants met criteria for hypercalcemia, there were no known supplement-related
adverse events, and major pregnancy outcomes were similar between groups.
Conclusions: Antenatal 3rd-trimester vitamin D3 supplementation (35,000 IU/week) significantly raised maternal and
cord serum 25(OH)D concentrations above 50 nmol/L in almost all participants without inducing hypercalcemia or
other observed safety concerns. Doses up to 35,000 IU/week may be cautiously used in further research aimed at
establishing the clinical effects and safety of vitamin D3 supplementation in pregnancy.
Trial registration: This trial was registered at ClinicalTrials.gov (NCT01126528).
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Vitamin D status during pregnancy has been proposed to
influence the risk of gestational diabetes and hypertensive
diseases of pregnancy [1], fetal skeletal growth [2], brain
development [3], and neonatal immune function [4]. The
major circulating vitamin D metabolite, 25-hydroxyvitamin
D (25(OH)D), crosses the placenta from the maternal to* Correspondence: daniel.roth@sickkids.ca
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reproduction in any medium, provided the orthe fetal circulation, thereby establishing fetal-neonatal
vitamin D stores [5]. However, the effects of vitamin D on
maternal, placental or fetal tissues are uncertain [2], and
the extent to which health outcomes are responsive to
changes in maternal-fetal vitamin D status remains un-
known [2,6,7].
Currently, there is insufficient evidence to either support
or refute the benefits of any given supplemental vitamin D
dose during pregnancy [8,9]. Moreover, the safety of high-
dose prenatal vitamin D regimens (i.e., doses that substan-
tially exceed the conventional prenatal intake of 400 tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Medicine (IOM) Committee to Review Dietary Reference
Intakes (DRIs) for Vitamin D and Calcium concluded in
2010 that the recommended dietary allowance (RDA) of
600 IU/day and tolerable upper intake level (UL) of
4000 IU/day for non-pregnant adults were suitable for
pregnant women [7]. The UL was doubled from 2000 IU/
day, as recommended by the IOM in 1997 [10], despite a
lack of new pregnancy trial safety data published between
1997 and 2010. Uncertainty surrounding vitamin D re-
quirements in pregnancy has led to divergent dose
recommendations; for example, the UNICEF antenatal
micronutrient formulation contains 200 IU/day [11], the
Canadian Paediatric Society has suggested 2000 IU/day
[12], and Hollis et al. advised an intake of 4000 IU/day
[13]. Similarly, the 25(OH)D threshold to define vitamin
D sufficiency is debated; the IOM set 50 nmol/L as a
lower limit of sufficiency [7], yet other expert bodies
such as the American Academy of Pediatrics have sug-
gested that pregnant women attain serum 25(OH)D
>80 nmol/L [14].
Determination of the vitamin D intake level (and corre-
sponding serum 25(OH)D concentration) that safely
optimizes vitamin D-responsive maternal-infant health
outcomes would have global implications, but may be par-
ticularly relevant to resource-poor communities in South
Asia, where a relatively low prenatal vitamin D status
overlaps with a high burden of morbidity and mortality as-
sociated with adverse birth and early infant health out-
comes [15]. In open-label pilot studies of high-dose
vitamin supplementation in non-pregnant and pregnant
women in Dhaka, Bangladesh, we showed that 35,000 IU/
week was well tolerated and raised 25(OH)D to >80 nmol/
L in pregnant women and newborns [16]. To more rigo-
rously establish the biochemical effects of this regimen,
and to provide evidence for a UL in pregnancy, we con-
ducted a randomized controlled trial (RCT) of 3rd-trimes-
ter vitamin D3 supplementation of 35,000 IU per week in
Dhaka. The primary aim of the study was to evaluate
the change in maternal and neonatal (cord blood) 25(OH)
D concentration and effects on serum calcium concen-
tration, and to generate preliminary data regarding preg-
nancy outcomes. These data may serve to design larger
RCTs to measure the effects of antenatal vitamin D
supplementation on functional outcomes of clinical and
public health importance.
Subjects and methods
Study design and participants
The Antenatal Vitamin D in Dhaka (AViDD) trial was a
double-blind placebo-controlled RCT conducted in
Dhaka, Bangladesh (23°N), through collaboration of the
International Center for Diarrheal Disease Research,
Bangladesh (icddr,b), The Johns Hopkins BloombergSchool of Public Health (Baltimore), and the Hospital
for Sick Children (Toronto). Enrolment of 160 partici-
pants occurred from August 2010 to January 2011,
and pregnancies were completed between September
2010 and April 2011. Participants were enrolled at the
Shimantik Urban Primary Health Care Project mater-
nity center, a non-governmental, non-profit facility that
provides basic antenatal and obstetric services (inclu-
ding cesarean deliveries) in a low-income area of Dhaka
(Khilgaon division). Participants were screened for eligi-
bility when they presented to the clinic for antenatal
care (ANC) visits during regular daytime clinic hours,
and were offered enrolment if they met the following
inclusion criteria: aged 18 to <35 years; gestational age
of 26 to <30 weeks, estimated based on the first day of
the last menstrual period (LMP); current residence in
Dhaka at a fixed address; planned to deliver at the
Shimantik maternity center, and to stay in Dhaka
throughout the pregnancy and for at least one month
past the date of delivery. Individuals were not eligible if
they had any of the following exclusion criteria: use of
any dietary supplement containing more than 400 IU/
day (10 mcg/day) of vitamin D within the month prior
to enrolment, or refusal to stop taking supplemental
vitamin D at any dose after enrollment; current use
of anti-convulsant or anti-mycobacterial (tuberculosis)
medications; severe anemia (hemoglobin < 70 g/L); sys-
tolic blood pressure ≥140 mm Hg or diastolic blood
pressure ≥90 mm Hg; positive urine dipstick for protein-
uria or glycosuria; complicated medical or obstetric his-
tory; or, reported prior history of delivery of an infant
with a major congenital anomaly, birth asphyxia, or
perinatal death. Informed consent was obtained from all
participants. The study was approved by ethical review
boards at The Johns Hopkins Bloomberg School of Public
Health, Hospital for Sick Children, and icddr,b. The trial
was registered at ClinicalTrials.gov (NCT01126528).
Intervention
Participants were randomly assigned to one of two
masked parallel intervention groups, with allocation
concealment: vitamin D3 (cholecalciferol) 35,000 IU/
week or matched placebo. The vitamin D3 was a high-
concentration (20,000 IU D3 per mL) liquid formulation
(Vigantol Oil, Merck KGaA, Germany), and the placebo
was miglyol oil 812 (Sasol, Germany), the vehicle used
in Vigantol Oil. Assignment was based on a computer-
generated randomization list, with 1:1 allocation, using
permuted blocks of size 4 and 8. The allocation se-
quence was prepared by icddr,b personnel not otherwise
involved in the study, and was concealed from investiga-
tors. Popular Pharmaceuticals Ltd. (Dhaka) prepared
the supplements off-site using individual opaque glass
vials labeled with unique participant identifiers based
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ambient temperature at the clinic throughout the study.
The active and placebo supplements were identical in
appearance and tasteless. Participants and research staff
(including lab personnel) were blinded to allocation.
Supplement doses were measured in disposable plastic
syringes and orally administered by study personnel, be-
ginning at the baseline visit and continuing thereafter at
7-day intervals until delivery. Missed doses could be
administered up to 7 days after the scheduled date, but
otherwise were skipped. Participants were advised to
discontinue all other supplements containing vitamin D,
and were offered prenatal iron and folic acid supple-
ments (66 mg elemental iron and 350 mcg/day folic acid
per day), routine antenatal monitoring, and obstetric
care free of charge.
Data collection and laboratory analyses
The baseline visit consisted of a detailed questionnaire,
anthropometry, blood pressure measurement, specimen
collection, and supplement administration. Thereafter,
participants were contacted weekly at their homes or in
the clinic for supplement administration and a ques-
tionnaire that included a checklist of symptoms related
to pregnancy complications and hypo-/hypercalcemia.
Random spot urine specimens were collected at base-
line, 2 weeks post-enrolment, and delivery. Venous
blood specimens were collected at baseline and once be-
tween gestational weeks 30 and 37 (the specific week
was randomly varied among participants); these speci-
mens were drawn immediately preceding the weekly
vitamin D dose administration; a third specimen was
collected around the time of delivery, irrespective of
when the last vitamin D dose was received. Study
personnel were on-call to attend deliveries at the mater-
nity center, where they completed a delivery record and
collected maternal and cord blood specimens. A phys-
ician examined all infants within 2 days of birth. New-
born weight was measured with a digital scale (Seca
354, Seca Corporation, Hanover, USA), length was mea-
sured using a locally-manufactured wooden length board.
Anthropometric results were the averages of paired re-
peated measures.
Maternal venous blood was collected into serum
separator tubes by standard methods, and cord blood
specimens were collected from the umbilical vein imme-
diately after delivery of the placenta. Maternal and cord
serum samples were maintained at 4°C prior to same-
day transfer to the laboratory. Serum aliquots were
frozen at −20°C and shipped at ambient temperature
from Bangladesh to Toronto for measurement of serum
25(OH)D concentration, a well-established biomarker of
systemic vitamin D status [17]. Serum 25(OH)D concen-
trations are unaffected by serum storage for several daysat refrigerated or room temperatures [18,19], and 25
(OH)D is resistant to multiple freeze-thaw cycles [18,20].
Serum 25(OH)D was quantified by high-performance
liquid chromatography tandem mass spectroscopy (LC-
MS/MS) in the Department of Pathology and Laboratory
Medicine at the Hospital for Sick Children. Briefly, in-
ternal standards (50 μL, 10 μmol/L) were added to 200
μL of serum, calibrator and control samples. Vitamin D
metabolites were extracted from the samples with 4 mL
of hexane/methanol (3:1). The excess solvent was eva-
porated to dryness under a stream of N2 gas at 37°C,
and the residue was re-dissolved in 100 μL of methanol
and analyzed by LC-MS/MS. Vitamin D metabolites
were separated on an Agilent 1100 series HPLC (Agilent
Technologies, USA) and a C18 column. The isocratic
mobile phase composition was A: 2 mmol/L ammonium
acetate in H2O + 0.1% formic acid, B: 2 mmol/L am-
monium acetate in methanol + 0.1% formic acid (10:90).
The API4000 QTRAP mass spectrometer (Applied
Biosystems/Sciex, Concord, ON, Canada) was equipped
with a TurboV electrospray ion source operated in the
positive mode. The ion transition of m/z 401.4→159.2 was
monitored for 25-hydroxyvitamin D3, m/z 407.3→158.9 for
D6-25-hydroxyvitamin D3 and m/z 413.4→107.2 for 25-
hydroxyvitamin D2; however, none of the samples were
found to contain detectable 25(OH)D2. This assay met
the performance targets of the international Vitamin D
External Quality Assessment Scheme (DEQAS) [21]. In a
quality control subsample, between-run correlation was
0.95 and the mean coefficient of variation (CV%) was
9.9%. Data were reported using 30 nmol/L and 50 nmol/L
cut-offs used in the IOM report [7] and the 80 nmol/L
threshold used in the Hollis trial [13].
Serum/urine aliquots were maintained at 4°C and ana-
lyzed within 48 hours of collection for serum calcium,
serum albumin, and urine calcium:creatinine ratio (ca:cr)
on the AU640 Olympus Autoanalyzer (Olympus Corpo-
ration, Japan) in the Clinical Biochemistry Laboratory at
icddr,b in Dhaka. Total serum calcium (Ca) concentration
was adjusted for the serum albumin concentration by the
following conventional formula: Ca + (0.02*(40-albumin)).
Intact parathyroid hormone (PTH) was measured at base-
line and delivery using a chemiluminescent microparticle
immune assay (i1000SR Architect Autoanalyzer, Abbott,
USA) at icddr,b.
Safety monitoring
Reported severe symptoms, persistence of any mild
symptomatic complaints for two consecutive visits, ab-
normal urinalyses, hypertension, or any other suspected
pregnancy complications prompted referral by study
personnel to the study physician for further evaluation.
Biochemical data were reviewed daily by the study phys-
ician and at least weekly by the principal investigator.
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used for safety monitoring was 2.60 mmol/L, which was
conservative relative to the threshold for defining hyper-
calcemia used by the IOM in setting the 1997 DRIs
for vitamin D (2.75 mmol/L) [10], and the threshold
cited by the IOM committee in its 2010 revision of the
vitamin D DRIs (2.63 mmol/L) [7]. Albumin-adjusted
serum calcium concentration (adj-Ca) above 2.60 mmol/L
prompted repeat blood sampling within 24 hours of the
first sample report to the physician. ‘Confirmed hypercal-
cemia’, the primary supplement-related adverse event
which would have prompted cessation of supplementa-
tion, was a priori defined as adj-Ca >2.60 mmol/L on two
separate consecutive blood specimens. This definition was
used because isolated values slightly above the upper limit
of the reference range were not considered to be consis-
tent with vitamin D toxicity. Urine ca:cr was expressed as
mmol Ca/mmol Cr, considering 1.0 as the upper limit of
the reference range [22]. Urine ca:cr was used as a screen-
ing test for possible hypercalcemia, such that unscheduled
blood sampling to measure serum calcium concentration
was performed if: two consecutive ca:cr > 1.0 mmol/mmol
values; or, ca:cr > 1.0 mmol/mmol on two non-consecutive
measurements but in the presence of persistent symp-
toms suggestive of possible hypercalcemia; or, ca:cr >
0.85 mmol/mmol on two consecutive urine specimens
that was also ≥2-fold greater than the baseline value in the
same participant. Participants with screen-positive urine
ca:cr as defined by one of the above three criteria were
also referred for renal ultrasound to rule-out the presence
of nephrocalcinosis or urinary tract calculi. Participants
were referred to an antenatal care physician at the mater-
nity clinic for treatment of urinary tract infections, hyper-
tension, or other medical problems diagnosed incidentally
during follow-up. Participants with obstetric or neonatal
complications were transported to a local tertiary-care
hospital. Major clinical decisions (e.g., labour induction,
cesarean deliveries) were the responsibility of non-study
physicians at Shimantik or referral hospitals; however,
costs of medical and obstetric care were borne by the
study. A data and safety monitoring board (DSMB) met at
regular intervals, but there were no a priori early stopping
criteria (see Additional file 1 for a note regarding an in-
terim DSMB review).
Statistical analysis
The primary pharmacokinetic outcome was the serum 25
(OH)D concentration and the primary safety measure was
adj-Ca concentration. The primary analysis employed an
intention-to-treat approach, including all data irrespective
of a participant’s adherence or duration of supplementa-
tion. Data were visualized using cross-sectional density
plots and longitudinal scatterplots with locally weighted
regression (lowess), and described by means, standarddeviations (SD) and 95% confidence intervals (95% CI), or
median and interquartile range (IQR) for variables with
skewed distributions. Analyses at 'delivery' were based on
specimens collected within +/− 1 day of delivery. Urinary
ca:cr at two weeks after enrollment was based on speci-
mens collected 14 +/−1 days after the first supplement
dose. Between-group differences in the mean maternal
and cord serum 25(OH)D, maternal Ca, adj-Ca, and PTH,
and maternal urinary ca:cr were analyzed at baseline and
delivery using linear regression for cross-sectional com-
parisons and generalized estimating equations (GEE) for
between-group differences in changes from baseline to de-
livery (to account for within-person correlation of paired
measures). PTH and urinary ca:cr were log and square-
root transformed, respectively, to approximate normality
for parametric tests. Bootstrapping was employed to con-
firm the robustness of inferences. In per-protocol sensitiv-
ity analyses, we only included participants who received at
least 8 consecutive weekly supplement doses and for
whom delivery serum specimens were available.
Change in mean 25(OH)D over time was modeled as a
continuous non-linear parametric function using a nega-
tive exponential growth function [16]. This approach en-
abled the estimation of the average difference in 25(OH)
D between the two groups at a presumed ‘steady-state’
(i.e., where group-averaged 25(OH)D did not continue
to appreciably rise despite ongoing vitamin D supple-
mentation). As a per-protocol sensitivity analysis, change
in mean 25(OH)D over time was modeled as a function
of cumulative dose (micrograms) of vitamin D actually
administered. Changes in serum Ca, adj-Ca, ca:cr, and
PTH concentrations were modeled longitudinally using
GEE with exchangeable correlation and robust variance
estimation. Serum Ca, adj-Ca and urine ca:cr demon-
strated non-linear trends over time in visual analysis by
lowess plots; therefore, piecewise (spline) linear regres-
sions were employed, with knot placement (the point on
the x-axis where the piecewise regression functions join)
for ca:cr ratio at day 14 (timing of scheduled urine col-
lection) and at day 60 for serum Ca and adj-Ca. Knot
placement was based on visual assessment of the trend
indicated by the lowess functions. In sensitivity analyses,
variation in knot placement did not change the infer-
ences of the model coefficients (data not shown). Clin-
ical outcomes were compared between groups using
Student’s t-test or Chi-square and Fischer’s exact test.
Frequencies of reported symptoms or minor clinical ad-
verse events, based on weekly clinical monitoring, were
analyzed using GEE where appropriate to estimate
between-group differences. Given the large number of
individual symptoms, the Holm procedure was used to
correct for multiplicity of pair-wise comparisons [23].
Data were entered in an electronic database (SQL Server
2005) using a custom-designed interface (Visual Basic
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in the data capture system to prevent errors in data
entry. Analyses were conducted using Stata version 11
(Stata Corporation, College Station, Texas) and R ver-
sion 2.15.1 (R Foundation for Statistical Computing,
Vienna, Austria).
The target sample size was 160 pregnant women, to
enable detection of a 0.5 SD difference in the primary
outcome (serum 25(OH)D concentration at delivery),
with a risk of a type I error rate (alpha) of 0.05, 80%
power, and accounting for up to 20% attrition prior to
delivery.
Results
Of the 160 participants recruited and randomly assigned
to either vitamin D (35,000 IU/week) or placebo, 13 were
lost to follow-up prior to delivery (6 in the placebo group
and 7 in the Vitamin D group), all because of having left
the Dhaka area (Figure 1). Serum specimens were avail-
able for all participants at baseline and for 130 (81.3%)
participants (63 placebo, 67 vitamin D) at delivery. Cord
blood specimens were collected from 67 and 65 mother-
infant pairs in the placebo and vitamin D groups, respect-
ively. Maternal characteristics and 25(OH)D at baseline
were similar in the placebo and vitamin D groups (Tables 1Figure 1 CONSORT diagram depicting the flow of participants throug
longitudinal analyses, 74 participants in the placebo group and 77 participa
beyond baseline.and 2). Weekly supplementation occurred over a median
period of approximately 10 weeks in both groups, and ad-
herence was excellent among participants who contrib-
uted biochemical outcome data (Table 3).
Most participants in both groups were vitamin D in-
sufficient by the IOM threshold (25(OH)D <50 nmol/L)
at baseline (Table 2). Vitamin D status at baseline did
not differ between the supplementation groups (Table 4)
nor between participants with and without delivery spe-
cimens (44.5 vs. 44.8 nmol/L, p = 0.94). Vitamin D sup-
plementation had a substantial, statistically significant
effect on maternal and neonatal vitamin D status at the
time of delivery, as reflected in the overall 25(OH)D dis-
tributions (Figure 2; Table 4) as well as the proportion of
participants considered to have low 25(OH)D using cut-
offs (Table 2). Notably, 100% of mothers (at delivery)
and 95% of neonates attained 25(OH)D >50 nmol/L
compared to only 21% and 19% of mother and neonates,
respectively, in the placebo group (Table 2). The highest
25(OH)D value in any participant was 200 nmol/L, ob-
served in a vitamin D group participant at delivery;
concurrently, her other biochemistry were normal (adj-
Ca, 2.47 mmol/L; urine ca:cr, 0.23 mmol/mmol). Longi-
tudinal analysis of the change in mean 25(OH)D over
time revealed an early and rapid rise in 25(OH)D, with ah the study. Data for all subjects were analyzed at baseline. In
nts in the vitamin D group contributed at least one biochemical value
Table 1 Participant baseline characteristics, overall and by treatment group
Characteristic Overall Placebo Vitamin D
(n = 160) (n = 80) (n = 80)
Age, yrs1 22.4 ± 3.5 22.4 ± 3.4 22.4 ± 3.5
Gestational age, weeks 27.8 ± 1.1 27.9 ± 1.0 27.6 ± 1.1
Marital status2
Married 160 (100) 80 (100) 80 (100)
Level of education
Primary school incomplete (<8 yrs) 102 (63.8) 50 (62.5) 52 (65.0)
High school incomplete (> = 8 to <12 yrs) 49 (30.6) 27 (33.8) 22 (27.5)
Graduate school (> = 12 yrs) 9 (5.7) 3 (3.8) 6 (7.5)
Primary occupation
Homemaker 141 (88.1) 72 (90.0) 69 (86.3)
Other 19 (11.9) 8 (10.2) 11 (14.0)
Number of pregnancies
Median 1 1 1
Range (Min, Max) (1, 5) (1, 4) (1, 5)
Number of live births
Median 0 0 0
Range (Min, Max) (0, 4) (0, 2) (0, 4)
Height, cm 150.3 ± 5.1 150.4 ± 5.4 150.3 ± 4.9
Weight, kg 52.0 ± 8.5 51.8 ± 9.1 52.2 ± 8.0
Body mass index (BMI) 23.0 ± 3.3 22.8 ± 3.5 22.1 ± 3.1
1 Mean ± standard deviation (SD).
2 n (%).
Table 2 Serum 25(OH)D categories at baseline and
delivery, by supplementation group
Placebo1 Vitamin D1 p2
Maternal Baseline (n = 80) (n = 80)
<30 nmol/L 21 (26.3) 18 (22.5) 0.88
30 – 49 nmol/L 32 (40.0) 32 (40.0)
50 – 79 nmol/L 21 (26.3) 25 (31.3)
> = 80 nmol/L 6 (7.5) 5 (6.3)
Maternal Delivery (n = 63) (n = 67)
<30 nmol/L 23 (35.9) 0 (0) <0.001
30 – 49 nmol/L 27 (42.2) 0 (0)
50 – 79 nmol/L 10 (15.9) 2 (3.0)
> = 80 nmol/L 3 (4.8) 65 (97.0)
Cord blood (n = 67) (n = 65)
<30 nmol/L 21 (31.3) 1 (1.5) <0.001
30 – 49 nmol/L 33 (49.3) 2 (3.1)
50 – 79 nmol/L 9 (13.4) 7 (10.8)
> = 80 nmol/L 4 (6.0) 55 (84.6)
1 n (%).
2 p-value for Chi-square test or Fischer’s exact test for proportions.
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mentation (Figure 3; Table 5). As evidence that this
plateau was not an artifact of diminishing supplement
adherence over time, a sensitivity analysis in which 25
(OH)D was modeled as a function of cumulative vitamin
D dose revealed the same pattern (Figure 3), and fit the
data well (Table 5). Vitamin D status declined in the
placebo group over time (Figure 3), but was not signifi-
cantly lower at delivery compared to baseline (38.3 vs.
44.0, p = 0.09).
Given the substantial inter-individual variability in the
response to vitamin D supplementation (Figure 3), we
explored the role of the following potential modifiers of
the magnitude of the change in 25(OH)D (Δ25(OH)D)
from baseline to delivery (selected a priori): maternal
weight at baseline, maternal age, gestational age, maternal
body mass index at baseline (BMI), gravidity, parity, base-
line PTH status, season and baseline vitamin D status.
None of these factors explained significant inter-individual
variability in the change in 25(OH)D status (data not
shown). Although Δ25(OH)D was inversely associated
with baseline vitamin D status, and about 24% of the vari-
ance in Δ25(OH)D in the vitamin D group was explained
by baseline 25(OH)D, this association appeared to be due
to regression to the mean, since similar trends were
observed in both the vitamin D and placebo groups. As
Table 3 Supplementation duration and adherence
Adherence Placebo Vitamin D p
Mean ± SD Median Range (min, max) Mean ± SD Median Range (min, max)
Time on study, weeks 9.7 ± 3.5 10.5 (0, 18) 9.8 ± 3.3 10 (0, 18) 0.871
Total supplement doses administered 10.5 ± 3.5 11 (1, 19) 10.6 ± 3.3 11 (1, 17) 0.83
Total vitamin D administered, mcg - - - 9469 ± 2424 9625 (875, 14000) -
Adherence, %2 99.2 ± 2.7 100 (84.6, 100) 99.4 ± 2.9 100 (80, 100) 0.79
Participants who received 100% of
scheduled doses, n (%)3
68 (91.9%) 69 (94.5%) 0.533
1 p-value for Student’s t-test for equality of means.
2 Adherence = (number of doses received divided by the number of doses scheduled) x 100. Analysis shown included participants who contributed 25(OH)D
measurements beyond baseline (n = 74 and n = 73 in placebo and vitamin D groups, respectively). Adherence for participants for whom delivery specimens were
available was similar: mean of 99.1% in the placebo group (n = 63) and 99.3% in the vitamin D group (n = 67). With respect to longitudinal analyses of changes in
25(OH)D over time, 206/219 serum specimens (93.5%) in the vitamin D group and 201/213 (94.4%) specimens in the placebo group were preceded by 100%
dose adherence.
3 Proportions shown were calculated among participants who contributed 25(OH)D measurements beyond baseline (74 in placebo group or 73 in the vitamin D
group); p value for chi-square test for proportions. Proportions in the subgroup of participants for whom delivery specimens were available were similar: 90.5% in
the placebo group (n = 63) and 94.0% in the vitamin D group (n = 67).
Table 4 Biochemical measures for maternal baseline, maternal delivery, and cord blood specimens, by
supplementation group
Biomarker (units) Placebo Vitamin D Group difference 1 Group-by-time effect2
(n = 80) (n = 80) Mean 95% CI Mean 95% CI
25(OH)D (nmol/L)
Baseline3 44.0 ± 20.9 45.4 ± 18.4 1.4 [−4.8, 7.5] – –
Delivery (n = 130)4 38.4 ± 18.1 134.4 ± 30.7 96.0*** [87.6, 104.8] 94.6*** [85.0, 104.1]
Cord (n = 132)5 39.0 ± 18.7 102.8 ± 28.6 63.9*** [55.8, 72.0] – –
Calcium (mmol/L)
Baseline 2.27 ± 0.09 2.25 ± 0.09 −0.02 [−0.04, 0.01] – –
Delivery (n = 130) 2.31 ± 0.11 2.32 ± 0.10 0.02 [−0.02, 0.05] 0.03 [−0.01, 0.07]
Albumin-adjusted calcium (mmol/L)
Baseline 2.36 ± 0.07 2.35 ± 0.07 −0.01 [−0.03, 0.01] – –
Delivery (n = 130) 2.40 ± 0.08 2.43 ± 0.09 0.03* [0.00, 0.06] 0.04* [0.01, 0.07]
PTH (pmol/L)6
Baseline 2.7 (0.3, 9.3) 2.9 (0.5, 9.4) 0.02 [−0.7, -0.2] – –
Delivery (n = 129)7 3.9 (0.3, 20.5) 2.3 (0.3, 9.8) −0.51*** [−0.8, -0.3] −0.53*** [−0.8, -0.3]
Urinary calcium-creatinine ratio (mmol/mmol) 8
Baseline 0.24 (0.0, 0.68) 0.22 (0.0, 0.88) −0.01 [−0.07, 0.05] – –
2 weeks (n = 151)9 0.26 (0.0, 1.11) 0.26 (0.0, 1.25) 0.03 [−0.04, 0.10] – –
Delivery (n = 125)10 0.13 (0.0, 1.26) 0.20 (0.0, 2.26) 0.04 [−0.05, 0.14] 0.07 [−0.03, 0.16]
1 Mean difference [95% CI] between the placebo and vitamin D group at a given time, by ordinary least square estimation.
2 Mean difference [95% CI] in the change for vitamin D versus placebo group (difference in the slope) using generalized estimation equations (GEE) to account for
within-subject correlations.
3 Mean ± standard deviation (SD).
4 Delivery specimens were those collected within +/−1 day of delivery; n = 63 and n = 67 in the placebo and vitamin D groups, respectively;
5 Cord serum available for n = 67 in the placebo and n = 65 in the vitamin D group.
6 Median (range) summarize maternal PTH concentrations, due to right-skewed distributions. PTH concentrations were log-transformed to approximate normality
for regression analyses. The results presented as group differences are log-transformed PTH concentrations.
7 PTH concentration at delivery available for n = 63 in placebo group and n = 66 in the vitamin D group.
8 Median (Range) summarize Ca: Cr ratios in the first two columns. Ca: Cr ratios were square root-transformed to approximate normality for regression analyses;
thus, the regression coefficients and confidence bounds are presented on a square-root scale.
9 Two-week specimens were defined as those collected 14 +/−1 days after enrolment.
10 Delivery urine samples were taken day of delivery, +/−1 day, n = 60 and n = 65 in the placebo and vitamin D groups, respectively.
*p-value < 0.05; **p-value 0.01; ***p-value < 0.001.
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AB
Figure 2 Maternal and cord serum 25-hydroxyvitamin D and serum parathyroid hormone concentration at baseline and delivery. (A)
Maternal and cord serum 25-hydroxyvitamin D (25(OH)D) concentrations, and (B) maternal serum parathyroid hormone (PTH) concentrations.
Kernel density plots, boxplots and jittered scatterplots illustrate the distribution of each subgroup. The limits of the box indicate the 25th and
75thpercentiles, and the black horizontal line within the box represents the median. (A) Black horizontal line within the scatterplot represents the
mean; (B) the black horizontal line within the scatterplot represents the geometric mean.
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delivery and cord 25(OH)D (Pearson correlation = 0.87,
p < 0.001), yet there was substantial variability among
mother-infant pairs with respect to the cord-to-maternal
ratio (ranged from 0.24 to 3.93). Notably, variation in cord
25(OH)D within the vitamin D group was not associated
with duration of supplementation (p = 0.86) or cumulative
vitamin D supplement dose administered (p = 0.93), indi-
cating that the maternal-fetal vitamin D equilibrium was
achieved rapidly.Mean maternal adj-Ca concentration rose over time
within the reference range; the initial rate of rise appeared
to be greater in the vitamin D group, but the difference
was attenuated after ~2 months of supplementation
(Figure 4). The mean adj-Ca at delivery and the change in
this parameter from baseline to delivery were slightly but
significantly greater in the vitamin D group versus placebo
(Table 4; Figure 5). Conversely, the between-group diffe-
rences in the mean total unadjusted serum Ca concentra-
tion at delivery and the change from baseline to delivery
AB
Figure 3 Maternal serum 25-hydroxyvitamin D (25(OH)D) concentration, by time or cumulative dose of vitamin D3. Thick lines represent
the negative exponential model-predicted serum 25(OH)D concentrations as a function of time (A) and as a function of cumulative dose of
vitamin D3 (B). Thin solid lines represent the 95% confidence interval (95% CI) around the predicted 25(OH)D. In panel B, all placebo group data
are clustered at 0 mcg given the lack of vitamin D3 supplementation. Model fit as assessed by R2 was 0.75 in both panels A and B.
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There were no cases of hypercalcemia in either group,
defined a priori as adj-Ca >2.60 nmol/L on two separate
consecutive blood specimens. One participant in the vita-
min D group exhibited an isolated adj-Ca value of 2.62 -
mmol/L at the time of delivery, in the context of an acute
diarrheal illness. Repeat measurements were 2.45 mmol/L
on both days 3 and 12 postpartum (see Additional file 2:
Table S3 for biochemical adverse events at any time du-
ring follow-up); therefore, trial criteria for hypercalcemia
were not met. This participant’s unadjusted total serum
Ca measurements were 2.48 mmol/L at delivery, 2.19
mmo/L at 3 days postpartum, and 2.41 mmol/L at 12 days
postpartum. Her calcium:creatinine ratio ranged from
0.02 to 0.22 mmol/mmol and 25(OH)D ranged from 22 to118 nmol/L. In secondary post-hoc analyses using all mater-
nal serum specimens in which 25(OH)D and calcium were
measured simultaneously, adj-Ca was significantly associated
with 25(OH)D at 25(OH)D < 100 nmol/L (0.02 mmol/L
[95% CI: 0.01, 0.03] increase in adj-Ca per 25 nmol/L
increase in 25(OH)D below 100 nmol/L; n = 331), but
this association was nullified and non-significant at 25(OH)
D > =100 nmol/L (−0.01 mmol/L [95% CI: -0.02, 0.01] per
25 nmol/L increase in 25(OH)D above 100 nmol/L; n = 102).
Urinary ca:cr rose marginally in both groups after the
first two weeks of supplementation, but declined thereafter
(Figure 4). Changes over time were similar in both groups
(Figure 4), and there were no significant differences in ca:
cr between the two groups at delivery (Table 4; Figure 5).
Hypercalciuria, defined a priori as ca:cr >1.0 mmol/mmol
Table 5 Estimates of the change in serum 25(OH)D concentration over time and by cumulative vitamin D3 dose
Model parameters (units) [25(OH)D] over time (days) in
Vitamin D group1
[25(OH)D] over time (days)
among all participants2
[25(OH]D] by dose (mcg)
among all participants2
β 95% CI [LB, UB] β 95% CI [LB, UB] β 95% CI [LB, UB]
Reference Day 0 (baseline) Placebo group at Day 0 (baseline) 0 mcg of Vitamin D
25(OH)D at ref. point (nmol/L) 45.5 [41.0, 49.9] 44.4 [39.7, 49.1] 42.1 [39.1, 45.1]
Difference in 25(OH)D between
groups at day 0 (nmol/L)
– 1.1 [−5.3, 7.6] –
Decay rate (days-1 or mcg-1) 0.04 [0.03, 0.05] 0.04 [0.03, 0.05] 0.0003 [0.0002, 0.0004]
Δ25(OH)D at steady-state in
placebo group (nmol/L)
– −7.1 [−12.3, -1.9] –
Effect of vitamin D on Δ25(OH)D
at steady-state (nmol/L)
94.4 [83.9, 104.9] 101.6 [89.7, 113.4]3 98.3 [88.7, 107.9]
Attained steady-state 25(OH)D (nmol/L) 139.9 [130.1, 149.6] 138.8 [127.4, 150.2] 140.4 [131.2, 149.6]
Adjusted R2 0.72 0.75 0.75
AIC – 3907.2 3904.4
180 participants in the vitamin D group, contributing 220 specimens. Negative exponential model (vitamin D group): [25(OH)D]t = [25(OH)D]t = 0 + a1(1 − e
− kt);
where t is time, a is the Δ25(OH)D (where Δ is the change from baseline) at steady-state in the placebo group, and k is the decay rate to the asymptote.
2 The models include 160 participants overall (n = 80 in each group) contributing 433 specimens. Negative exponential model (both groups):
[25(OH)D]t = [25(OH)D]t = 0 + β g + (gd + a0)(1 − e
− kt); where t is time, a is the Δ25(OH)D at steady-state in the placebo group, k is the decay rate to asymptote, g is
group assignment and d is the difference in Δ25(OH)D between groups at steady-state,
3 Difference in Δ25(OH)D between placebo and vitamin D groups at modeled steady-state.
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participant in the vitamin D group, at 29 weeks gesta-
tion on day 14 of follow-up. Ca:cr was 1.08 mmol/mmol
on day 14 and 1.11 mmol/mmol on day 16, but was nor-
mal at delivery (0.23 mmol/mmol) after continuation
of vitamin D supplementation for a total of 10 weeks
(cumulative dose of 9625 mcg). Throughout follow-up,
this participant’s adj-Ca was within the reference range
(2.32 to 2.55 mmol/L) and 25(OH)D concentration
ranged from 54 – 147 nmol/L. A renal ultrasound
showed an absence of nephrocalcinosis or renal calculi,
and there were no associated clinical consequences.
Transient hypercalciuria, defined as one ca:cr measure-
ment above 1.0 mmol/mmol, was observed in 3 (4.1%)
participants in the placebo group and 4 (5.5%) in the
vitamin D group (p = 0.72 for between-group diffe-
rence). Similarly, the proportion of participants with a
ca:cr >0.8 mmol/mmol and >2-fold difference from
baseline did not differ significantly between the two
groups (2.7% vs. 5.5%, p = 0.44).
Vitamin D supplementation had a significant suppre-
ssive effect on maternal PTH concentration, such that
the rise in PTH observed in the placebo group was com-
pletely attenuated in the vitamin D group (Figure 4), and
the average PTH concentration was lower in the vitamin
D group at delivery (Figure 2; Table 4). Detailed weekly
clinical monitoring did not reveal significant differences
in reported symptom or minor adverse event frequencies
between the two groups (online supplemental material).
In particular, the overall proportion of encounters in
which there was at least one symptom possibly suggest-
ive of hypercalcemia was similar for the placebo andvitamin D groups (54% vs. 53%, p = 0.71; analysis accounted
for repeated events within the same participants). Major
pregnancy/birth outcome and serious clinical adverse event
frequencies and distributions were similar across the two
groups (Table 6).
Discussion
Among pregnant women with relatively low average base-
line vitamin D status in Dhaka, 3rd-trimester vitamin D3
supplementation (35,000 IU/week) significantly raised ma-
ternal and neonatal (cord blood) serum 25(OH)D concen-
trations above the IOM cut-off for sufficiency (50 nmol/L)
in virtually all participants without inducing hypercalce-
mia or other apparent short-term clinical adverse effects.
This study contributes pharmacokinetic data relevant to
South Asia, as well as preliminary evidence in support of a
vitamin D3 no observed adverse effect level (NOAEL) of
35,000 IU/week in the third trimester of pregnancy.
The present findings build primarily on those of Hollis
et al. in South Carolina, who randomized 502 pregnant
women at 12 to 16 weeks gestation to receive vitamin D3
at doses of 400 IU/day, 2000 IU/day, or 4000 IU/day; 350
participants (70%) were followed-up until delivery [13].
From a baseline 25(OH)D of 58 nmol/L, 2000 IU/day and
4000 IU/day raised 25(OH)D to means at the time of de-
livery of 98 nmol/L (rise of 40 nmol/L) and 111 nmol/L
(rise of 52 nmol/L), respectively [13]. In the 4000 IU/day
group, 82% attained 80 nmol/L at delivery, compared to
97% in the present study (5000 IU/day). In 2012, Dawodu
et al. presented unpublished findings from a trial in United
Arab Emirates in which 2000 IU/day and 4000 IU/day
raised mean 25(OH)D from ~20 nmol/L to ~65 nmol/L
AB
C
Figure 4 (See legend on next page.)
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Figure 4 Maternal albumin-adjusted serum calcium concentration (A), calcium:creatinine ratio (B), and serum parathyroid hormone
concentration (C), by time. Group means were modeled using piecewise linear regression (panels A and B) and generalized estimative equations
(GEE). (A) Knot was placed at day 60, and the change in slope at that point was statistically significant in the vitamin D group (p < 0.01), but not in the
placebo group. Associations: before knot in vitamin D group = 0.044 mmol/L per month, (p < 0.001); after knot in vitamin D group = −0.028 mmol/L
per month, (p = 0.141); before knot in the placebo group = 0.017 mmol/L per month, (p < 0.01); after knot in the placebo group = 0.000 mmol/L per
month, (p = 0.997). (B) Calcium:creatinine ratio was square-root transformed prior to regression analysis. A knot was placed at day 14, where the
change in slope was statistically significant in the vitamin D group (p < 0.01), but not in the placebo group. Associations: before knot in the vitamin D
group = 0.147 mmol/mmol per month, (p < 0.05); after knot in vitamin D group = −0.042 mmol/mmol per month, (p < 0.05); before knot in placebo
group = 0.052 mmol/mmol per month, (p = 0.311); after knot in placebo group = −0.048 mmol/mmol per month, (p < 0.01). Varying the knot location
in sensitivity analyses did not substantially change the inferences from panels A or B. (C) Parathyroid hormone concentrations were log transformed
prior to regression analyses. There was a significant increase over time in the placebo group (0.01 log-pmol/L [95% CI: 0.003, 0.008] for each day
increase in follow-up time; p < 0.001), but the slope of the vitamin D group was significantly attenuated (0.007 log-pmol/L [95% CI: -0.01, -0.004] lower
than in the placebo group; p < 0.001).
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delivery, respectively [24]. Our modeled mean increment
in maternal 25(OH)D of 102 nmol/L corresponded to a
rise of 0.82 nmol/L/mcg/day (95% CI, 0.72 to 0.91), which
was similar to the value often cited for non-pregnant adults
(~0.7 nmol/L/mcg/day [25,26]) but smaller than the effect
observed with lower vitamin D3 doses (e.g., 1.6 nmol/L/
mcg/day for doses of ~800 IU/day [27]). This is consistent
with the hypothesized constraint in hepatic vitamin D–to–
25(OH)D conversion that occurs at a 25(OH)D concentra-
tion of about 80–90 nmol/L [28].
In a preceding pilot trial in Dhaka, we found that 3rd-
trimester regimens of 14,000 IU/week (≈2000 IU/day) and
35,000 IU/week (≈5000 IU/day) led to mean 25(OH)D
concentrations of 76 nmol/L (rise of 36 nmol/L) and
98 nmol/L (rise of 57 nmol/L), respectively, after 10 weeks
of supplementation [16]. Thus, compared to the present
study, the average response to 35,000 IU/week was less
pronounced in the pilot study. However, direct between-
study comparisons are tempered by differences in study
design (e.g., shorter period of follow-up in the pilot study)
and 25(OH)D assays. In comparison to the LC-MS/MS
method used here, the immunoassay used in the pilot
study (Diasorin Liaison Total) may have under-estimated
25(OH)D because of raised DBP concentrations in preg-
nancy [29] or relative imprecision at the higher 25(OH)D
range attained in the vitamin D group [30,31].
Similar to previous trials [13,16], we observed substantial
inter-individual variability in the maternal Δ25(OH)D, such
that the SD on the mean 25(OH)D nearly doubled from
18.4 nmol/L at baseline to 30.7 nmol/L at delivery in the
vitamin D group; in contrast, in the placebo group, the SD
at baseline was 20.1 nmol/L and at delivery was 18.1 nmol/
L. However, we could not identify any participant factor
other than intervention group that significantly explained
Δ25(OH)D. The range of published mean cord blood
25(OH)D concentrations in South Asia, from 21 [32] to 59
[33] nmol/L, bounds the mean cord 25(OH)D of 39 nmol/
L in the control group. A normal cord 25(OH)D range
based on functional outcomes has not been defined;however, Zeghoud et al. (1997) reported that newborn
25(OH)D > 30 nmol/L was associated with suppression of
PTH concentrations [34], and 25(OH)D > 50 nmol/L (the
25(OH)D threshold for sufficiency set by the IOM) has
been associated with a low risk of rickets [35]. In our study,
95% of newborns had a cord-maternal 25(OH)D ratio
of 0.5 to 1.5, suggesting that universal maternal prenatal
25(OH)D > 100 nmol/L would ensure that nearly all cord
concentrations are above 50 nmol/L.
We remain guarded in our interpretation of these
pharmacokinetic data because the clinical implications
of the observed changes in maternal-fetal 25(OH)D and
resultant maternal PTH suppression in pregnancy re-
main to be defined. Hollis et al. concluded from their
trial findings “that the current vitamin D EAR and RDA
for pregnant women issued in 2010 by the IOM should
be raised to 4000 IU of vitamin D per day” [13]. How-
ever, we do not believe that above-RDA doses should yet
be recommended as routine practice. Further clinical
data are required before conclusive statements can be
made regarding the appropriateness of high-dose ante-
natal vitamin D supplementation. However, like Hollis
et al., we did not encounter any evidence of vitamin D
toxicity. Vitamin D did not affect average urinary calcium
excretion, yet we did see a small but significant increase in
the mean adj-Ca in the vitamin D group compared to the
placebo group. Several factors suggested this was not
likely to be evidence of harm. First, this trend was attenu-
ated and non-significant when the analysis involved
uncorrected serum calcium, a less conservative endpoint
used in previous trials. Second, we did not observe a linear
escalation in adj-Ca over the entire duration of supple-
mentation, but rather found an initial increase in the rate
of the natural rise in adj-Ca that occurs in late pregnancy
[36] followed by an attenuation of the between-group dif-
ference after about 2 months of supplementation. This
suggested a homeostatic adjustment to the altered vitamin
D status, with no further increase in serum calcium after a
steady-state 25(OH)D was reached. Third, a positive asso-
ciation between adj-Ca and 25(OH)D was apparent in the
AB
Figure 5 Maternal albumin-adjusted serum calcium (A) and urine calcium:creatinine ratio (B), at baseline, day 14 and delivery.
Specimens were collected at baseline, 14 days after enrolment (for urine ca:cr) and at delivery. Kernel density plots, boxplots and jittered
scatterplots illustrate the distribution of each subgroup. Upper and lower bounds of the box illustrate the 25th and 75th percentiles, and the black
horizontal line within the box represents the median. (A) The black horizontal line within the scatterplot represents the mean; (B) black horizontal
line within the scatterplot represents the square of the mean of square root-transformed ca:cr.
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100 nmol/L; evidence of possible harm would be more con-
sistent with the opposite finding of a serum calcium that
was tightly controlled (i.e., unassociated with 25(OH)D)
within the lower range of 25(OH)D, but deflected upward
at higher 25(OH)D. All maternal uncorrected and adj-Ca
values were below the threshold for hypercalcemia used by
the IOM in the 1997 vitamin D DRIs (2.75 mmol/L) [10]
and the 2010 revision (2.63 mmol/L) [7]. We set a con-
servative upper limit of reference range for trial moni-
toring (2.60 mmol/L), which was crossed by one
participant in the vitamin D group; however, this wasnot logically attributable to vitamin D toxicity based
on normal repeat serum calcium, normal ca:cr, and a
25(OH)D that was well within the range considered to be
non-hypercalcemic [37]. Based on biochemical findings,
and the lack of apparent clinical adverse effects, we cau-
tiously conclude that 35,000 IU/week for an average of
10 weeks (up to 18 weeks) was tolerated by study partici-
pants, and could be considered an upper dose limit for use
in future research.
This RCT had several limitations. It was not designed
to draw precise inferences regarding pregnancy/birth
outcomes, which limits its clinical applications. The
Table 6 Pregnancy outcomes and neonatal anthropometry, overall and by study group
Outcome Overall Placebo Vitamin D p2
(n = 147) (n = 74) (n = 73)
Location of delivery1
Shimantik Maternity centre 124 (84.4) 62 (83.8) 62 (84.9) 1.00
Home 13 (8.8) 7 (9.7) 6 (8.2)
Other hospital or clinic 1 (0.7) 0 (0) 1 (1.4)
Other 9 (6.1) 5 (6.8) 4 (5.5)
Mode of delivery
Vaginal 59 (40.1) 30 (40.5) 29 (39.7) 1.00
C-section 88 (59.7) 44 (59.7) 44 (60.3)
Vaginal delivery3
Spontaneous 54 (91.5) 28 (93.3) 26 (89.7) 0.80
Forceps 3 (5.1) 1 (3.3) 2 (6.9)
Unknown 2 (3.4) 1 (3.3) 1 (3.5)
Indication for c-section4
Urgent 76 (81.7) 41 (89.1) 35 (74.5) 0.17
Elective 11 (11.8) 3 (6.5) 8 (17.0)
Unknown 6 (6.5) 2 (4.4) 4 (8.5)
Maternal serious clinical adverse events5 4 (2.5) 2 (2.7) 2 (2.7) 1.00
Gestational age at birth, wks6 38.4 ± 2.1 38.5 ± 2.1 38.2 ± 2.1 0.31
Infant anthropometry
Birth weight, g7 2795 ± 467 2788 ± 378 2802 ± 543 0.86
Length at birth, cm8 48.1 ± 2.5 48.0 ± 2.0 48.2 ± 2.5 0.55
Head circumference, cm9 33.0 ± 1.7 33.0 ± 1.5 32.9 ± 1.8 0.71
Total births registered10 147 (91.9) 74 (92.5) 73 (91.3) 0.77
Live births11 145 (98.6) 73 (98.6) 72 (98.6) 0.99
Stillbirths11 2 (1.4) 1 (1.4) 1 (1.4) 1.00
Neonatal clinical adverse events
Neonatal serious non-fatal adverse events 13 (8.8) 7 (9.5) 6 (8.2) 0.81
Neonatal deaths 4 (2.8) 3 (4.1) 1 (1.4) 0.62
1 n (%).
2 p-value for Student’s t-test for means and Fischer’s exact test for proportions, conducted for variables with cell counts <5.
3 n = 59, as mode of delivery was vaginal.
4 n = 88, as mode of delivery was c-section.
5 Maternal serious adverse events included gastroenteritis, preterm delivery with premature rupture of membranes, injury (15% flame burn), and pre-eclampsia.
6 Mean ± standard deviation (SD).
7 Birth weight was missing for 2 infants in the placebo group and 1 in the vitamin D group.
8 n = 137 (69 in placebo, 68 in the vitamin D group).
9 n = 132 (65 in placebo, 67 in vitamin D group).
10 Denominator for calculation of proportions was the total number of women enrolled (n = 160).
11 Denominator for calculation of proportions was the total number of births registered (n = 147).
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proved by the inclusion of other dose levels. Because of
the high dose of vitamin D not previously studied in preg-
nancy, enrolment was limited to healthy women at low
risk of pregnancy complications, and who were most likely
to adhere to the protocol; as such, generalizability of the
findings may be limited. In addition, enrolment was not
conducted throughout the entire season, but rather oc-
curred during a period in which vitamin D status was de-
clining from its summer peak. Mechanistic inferences were
limited because we did not measure serum concentrationsof 1,25(OH)2D, vitamin D3, or DBP. As well, we did not
calculate total intake of vitamin D due to the lack of ad-
equate information regarding vitamin D content in the
Bangladeshi food supply.
Conclusions
In conclusion, this RCT in Dhaka enabled a detailed
characterization of the biochemical response to 35,000 IU/
week vitamin D3 supplementation in the third-trimester
of pregnancy. Future studies involving equal or lesser
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http://www.nutritionj.com/content/12/1/47doses are required to establish maternal-infant benefits
and longer-term safety.
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